Compare WKC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WKC | AGIO |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1994 | 2013 |
| Metric | WKC | AGIO |
|---|---|---|
| Price | $22.76 | $27.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $28.00 | ★ $37.63 |
| AVG Volume (30 Days) | 703.3K | ★ 708.3K |
| Earning Date | 05-22-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,916,600,000.00 | $43,011,000.00 |
| Revenue This Year | $0.67 | $75.68 |
| Revenue Next Year | $5.28 | $167.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.71 | $22.24 |
| 52 Week High | $29.85 | $46.00 |
| Indicator | WKC | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 24.20 | 46.37 |
| Support Level | N/A | $26.48 |
| Resistance Level | $26.55 | $29.49 |
| Average True Range (ATR) | 0.59 | 1.13 |
| MACD | -0.22 | -0.17 |
| Stochastic Oscillator | 3.05 | 25.09 |
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. The company earns the majority of its revenue from the Aviation segment.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.